Skip to main content
ADPT
NASDAQ Life Sciences

Adaptive Biotechnologies Officer & Director Files Intent to Sell $6.8M in Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$13.32
Mkt Cap
$2.051B
52W Low
$6.675
52W High
$20.76
52W Position info
100% above low
Off High info
36% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ADPT sits 100% above its 52-week low of $6.675.

Summary

An Officer and Director of Adaptive Biotechnologies has filed a Form 144 to sell approximately $6.8 million worth of stock, continuing a pattern of significant insider selling.


Key Events · Ownership and Investor Activity · ADPT

  • Officer & Director Files Intent to Sell

    Chad M. Robins, an Officer and Director, filed a Form 144 to sell 470,167 shares of common stock, valued at approximately $6.8 million.

  • Follows Recent Vesting

    The shares intended for sale were acquired upon the vesting of restricted stock units and performance stock units on March 4, 2026.

  • Part of Ongoing Insider Distribution

    This proposed sale adds to a pattern of significant insider selling by Robins, who has already sold over $12.5 million in shares in the past three months. The company has seen over $32 million in net insider selling across all insiders in the last 90 days.


Analysis · ADPT · Life Sciences

Chad M. Robins, an Officer and Director of Adaptive Biotechnologies, has filed a Form 144 indicating an intent to sell 470,167 shares of common stock, valued at approximately $6.8 million. This proposed sale follows the recent vesting of restricted stock units and performance stock units. This transaction is part of a broader pattern of significant insider distribution, with Robins having sold over $12.5 million in shares in the past three months, contributing to a total net insider selling of over $32 million across the company in the last 90 days. While often related to liquidity or tax planning, a substantial and ongoing selling trend by a key executive can be perceived negatively by investors, especially following the company's recent positive financial results.

At the time of this filing, ADPT was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.68 to $20.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Jul 01, 2026, 4:35 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $22.76
Real-time Price: $22.45 info
Change: -$0.3141 (-1%) info
Market Cap: $3.604B info
ADPT
Jun 22, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.37
Real-time Price: $22.45 info
Change: +$5.08 (+29%) info
Market Cap: $3.604B info
ADPT
Jun 17, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $17.13
Real-time Price: $22.45 info
Change: +$5.32 (+31%) info
Market Cap: $3.604B info
ADPT
Jun 15, 2026, 4:50 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.50
Real-time Price: $22.45 info
Change: +$5.95 (+36%) info
Market Cap: $3.604B info
ADPT
Jun 15, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.97
Real-time Price: $22.45 info
Change: +$6.48 (+41%) info
Market Cap: $3.604B info